Evidence map›Paper›PMID 25262443›Full record

ArticleSchizophrenia bulletin2015

Mortality in schizophrenia and other psychoses: a 10-year follow-up of the ӔSOP first-episode cohort.

Ulrich Reininghaus, Rina Dutta, Paola Dazzan, Gillian A Doody, Paul Fearon, Julia Lappin, Margaret Heslin, Adanna Onyejiaka, Kim Donoghue, Ben Lomas and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 7 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 7 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Ulrich Reininghausulrich.reininghaus@kcl.ac.uk.
Rina DuttaDepartment of Psychological Medicine, Institute of Psychiatry, King's College, London, UK;
Paola DazzanNIHR Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College, London, UK; Psychosis Studies Department, Institute of Psychiatry, King's College, London, UK;
Gillian A DoodyDivision of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK;
Paul FearonDepartment of Psychiatry, Trinity College, Dublin, Ireland;
Julia LappinNIHR Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College, London, UK; Psychosis Studies Department, Institute of Psychiatry, King's College, London, UK; Department of Psychiatry, University of New South Wales, Sydney, NSW, Australia;
Margaret HeslinCentre for Economics of Mental and Physical Health, Health Service and Population Research Department, Institute of Psychiatry, King's College, London, UK;
Adanna OnyejiakaCentre for Epidemiology and Public Health, Health Service and Population Research Department, Institute of Psychiatry, King's College, London, UK;
Kim DonoghueAddictions Department, Institute of Psychiatry, King's College, London, UK;
Ben LomasDivision of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK;
James B KirkbrideDivision of Psychiatry, University College London, London, UK;
Robin M MurrayNIHR Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College, London, UK; Psychosis Studies Department, Institute of Psychiatry, King's College, London, UK;
Tim CroudaceDepartment of Health Sciences, University of York, York, UK.
Craig MorganCentre for Epidemiology and Public Health, Health Service and Population Research Department, Institute of Psychiatry, King's College, London, UK; NIHR Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College, London, UK;
Peter B JonesDepartment of Psychiatry, University of Cambridge, National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and NIHR Collaboration for Leadership in Applied Health Research & Care, Cambridge, UK;
King's College London · GBUniversity of Nottingham · GBKing's College School · GBNIHR Applied Research Collaboration Greater ManchesterTrinity College Dublin · IEUniversity College London · GBUniversity of York · GB

Funding

Department of Health PDF-2011-04-065Department of Health RP-PG-0606-1335Medical Research Council G0001354Medical Research Council G0500817Medical Research Council G0600972Medical Research Council G106/1148Wellcome Trust 087417Wellcome Trust 095844Wellcome Trust 101272Wellcome Trust 101272/Z/13/Z
6 · The paper itself

Abstract

The excess mortality in people with psychotic disorders is a major public health concern, but little is known about the clinical and social risk factors which may predict this health inequality and help inform preventative strategies. We aimed to investigate mortality in a large epidemiologically characterized cohort of individuals with first-episode psychosis compared with the general population and to determine clinical and social risk factors for premature death. All 557 individuals with first-episode psychosis initially identified in 2 areas (Southeast London and Nottinghamshire, United Kingdom) were traced over a 10-year period in the ӔSOP-10 study. Compared with the general population, all-cause (standardized mortality ratio [SMR] 3.6, 95% confidence interval [CI] 2.6-4.9), natural-cause (SMR 1.7, 95% CI 1.0-2.7) and unnatural-cause (SMR 13.3, 95% CI 8.7-20.4) mortality was very high. Illicit drug use was associated with an increased risk of all-cause mortality (adj. rate ratio [RR] 2.31, 95% CI 1.06-5.03). Risk of natural-cause mortality increased with a longer time to first remission (adj. RR 6.61, 95% CI 1.33-32.77). Family involvement at first contact strongly reduced risk of unnatural-cause mortality (adj. RR 0.09, 95% CI 0.01-0.69). Our findings suggest that the mortality gap in people with psychotic disorders remains huge and may be wider for unnatural-cause mortality than previously reported. Efforts should now focus on further understanding and targeting these tractable clinical and social risk factors of excess mortality. Early intervention and dual diagnosis services may play a key role in achieving more rapid remission and carer involvement and addressing substance use problems to reduce excess mortality in psychosis.

Indexed as

Cause of DeathRegistriesAdolescentAdultAgedEnglandFemaleFollow-Up StudiesHumansLondonMaleMiddle AgedPsychotic DisordersRiskSchizophreniaTime Factorsmortality/psychosis/risk factorsschizophrenia/

Identifiers

PMID25262443
PMCPMC4393685
OpenAlexW2170663130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.